Apellis Pharmaceuticals (APLS) Insider Trading & Ownership $31.24 +0.47 (+1.53%) (As of 03:16 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Apellis Pharmaceuticals (NASDAQ:APLS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage6.80%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)12Amount OfInsider Selling(Last 12 Months)$33.30 M Get APLS Insider Trade Alerts Want to know when executives and insiders are buying or selling Apellis Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address APLS Insider Buying and Selling by Quarter Ad DTILet’s be bluntLet me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now Apellis Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/16/2024A. Sinclair DunlopDirectorSell37,000$36.23$1,340,510.00 6/21/2024A. Sinclair DunlopDirectorSell37,000$39.24$1,451,880.00 5/8/2024Pascal DeschateletsInsiderSell78,907$42.35$3,341,711.45 4/8/2024Pascal DeschateletsInsiderSell69,107$54.17$3,743,526.19 4/1/2024Timothy Eugene SullivanCFOSell4,000$58.66$234,640.00 3/19/2024A. Sinclair DunlopDirectorSell18,681$57.18$1,068,179.58 I've got news for you… (Ad)Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the weekwatch this FREE briefing with me and expert trader Graham Lindman3/18/2024Mark Jeffrey DelongInsiderSell9,913$56.90$564,049.70 3/15/2024James George ChopasCAOSell184$56.46$10,388.64 3/13/2024Nur NicholsonInsiderSell11,220$57.56$645,823.20 3/1/2024Cedric FrancoisCEOSell250,000$64.11$16,027,500.00 3/1/2024Timothy Eugene SullivanCFOSell6,000$63.22$379,320.00 2/12/2024Adam J TownsendInsiderSell1,148$67.77$77,799.96 2/12/2024Cedric FrancoisCEOSell3,962$67.77$268,504.74 2/12/2024David O WatsonGeneral CounselSell781$67.77$52,928.37 2/12/2024Timothy Eugene SullivanCFOSell1,431$67.77$96,978.87 1/29/2024Cedric FrancoisCEOSell2,843$64.14$182,350.02 1/29/2024David O WatsonGeneral CounselSell906$64.14$58,110.84 1/29/2024Nur NicholsonInsiderSell835$64.14$53,556.90 1/22/2024Adam J TownsendInsiderSell3,413$65.00$221,845.00 1/22/2024Cedric FrancoisCEOSell13,431$65.00$873,015.00 1/22/2024David O WatsonGeneral CounselSell4,184$65.00$271,960.00 1/22/2024James George ChopasCAOSell1,061$65.00$68,965.00 1/22/2024Timothy Eugene SullivanCFOSell3,551$65.00$230,815.00 1/16/2024Cedric FrancoisCEOSell7,851$66.81$524,525.31 1/16/2024David O WatsonGeneral CounselSell4,240$66.81$283,274.40 1/16/2024James George ChopasCAOSell864$66.81$57,723.84 1/16/2024Jeffrey EiseleInsiderSell438$66.81$29,262.78 1/16/2024Timothy Eugene SullivanCFOSell2,235$66.81$149,320.35 1/4/2024Caroline BaumalInsiderSell2,751$60.05$165,197.55 12/26/2023Jeffrey EiseleInsiderSell68$57.86$3,934.48 12/19/2023David O WatsonGeneral CounselSell3,905$57.23$223,483.15 12/1/2023Lukas ScheiblerInsiderSell10,000$60.00$600,000.00 (Data available from 1/1/2013 forward) APLS Insider Trading Activity - Frequently Asked Questions Who is on Apellis Pharmaceuticals's Insider Roster? The list of insiders at Apellis Pharmaceuticals includes A. Sinclair Dunlop, Adam J Townsend, Alec Machiels, Caroline Baumal, Cedric Francois, David O Watson, Federico Grossi, James George Chopas, Jeffrey Eisele, Karen Lewis, Lukas Scheibler, Mark Jeffrey Delong, Nur Nicholson, Pascal Deschatelets, Timothy Eugene Sullivan, and Victoria L Brown. Learn more on insiders at APLS. What percentage of Apellis Pharmaceuticals stock is owned by insiders? 6.80% of Apellis Pharmaceuticals stock is owned by insiders. Learn more on APLS's insider holdings. Which Apellis Pharmaceuticals insiders have been selling company stock? The following insiders have sold APLS shares in the last 24 months: A. Sinclair Dunlop ($3,947,909.58), Adam J Townsend ($1,497,844.96), Alec Machiels ($847,862.50), Caroline Baumal ($165,197.55), Cedric Francois ($32,763,087.07), David O Watson ($1,655,486.56), Federico Grossi ($246,800.00), James George Chopas ($165,872.49), Jeffrey Eisele ($192,963.30), Karen Lewis ($957,418.90), Lukas Scheibler ($600,000.00), Mark Jeffrey Delong ($570,080.94), Nur Nicholson ($1,600,274.60), Pascal Deschatelets ($15,635,237.64), and Timothy Eugene Sullivan ($7,897,356.05). How much insider selling is happening at Apellis Pharmaceuticals? Insiders have sold a total of 1,171,076 Apellis Pharmaceuticals shares in the last 24 months for a total of $68,743,392.14 sold. Apellis Pharmaceuticals Key ExecutivesDr. Cedric Francois M.D. (Age 52)Ph.D., Co-Founder, President, CEO & Director Compensation: $1.44MMr. Alec Machiels J.D. (Age 51)MBA, Co-Founder & Director Compensation: $90.62kMr. Timothy E. Sullivan (Age 53)CFO & Treasurer Compensation: $793.43kMr. Adam J. Townsend (Age 46)Chief Operating Officer Compensation: $770.44kMr. David O. Watson Esq. (Age 51)J.D., General Counsel Compensation: $764.37kDr. Caroline R. Baumal M.D. (Age 56)Chief Medical Officer Compensation: $1.01MDr. Pascal Deschatelets Ph.D. (Age 54)Co-Founder & Chief Scientific Officer Compensation: $688.05kMr. James G. Chopas CPA (Age 57)VP, Corporate Controller & Chief Accounting Officer Ms. Meredith KayaSenior Vice President, Investor Relations & Strategic FinanceMs. Karen Lewis (Age 51)Chief People Officer More Insider Trading Tools from MarketBeat Related Companies Omeros Insider Transactions Rigel Pharmaceuticals Insider Transactions Seres Therapeutics Insider Transactions Summit Therapeutics Insider Transactions Genmab A/S Insider Transactions Vaxcyte Insider Transactions Catalent Insider Transactions Sarepta Therapeutics Insider Transactions Revolution Medicines Insider Transactions Intra-Cellular Therapies Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:APLS) was last updated on 11/25/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
